An observational study in IOL, Cataract, sponsored by Rayner Intraocular Lenses Limited. Not yet recruiting. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Rayner Intraocular Lenses Limited · Observational
The goal of this post-market, prospective study at multiple clinics is to evaluate the rotational stability of the RayOne Model RAO800S non-toric monofocal intraocular lens with orientation marks in adult patients undergoing cataract surgery in both eyes. The main question it aims to answer is how stable the RayOne RAO800S lens is approximately 5 months (120 to 150 days) after surgery day. Participants are adults already scheduled to undergo cataract surgery as part of clinical routine. They will be asked to attend regular follow-up visits at the clinic, where eye images will be taken to assess the rotational stability of the implanted lens.
This post-market clinical follow-up (PMCF) study is a prospective, multicenter investigation in European sites. It evaluates the rotational stability of the RayOne Model RAO800S, a non-toric monofocal intraocular lens with orientation marks, following bilateral implantation. Participants will be assessed approximately 5 months (120 to 150 days) post-operatively.
165 studies on the registry are indexed under Intraocular Lymphoma; 9 are open to participants now.
This study's planned enrollment of 92 is above the median of 64 across 20 observational studies indexed under Intraocular Lymphoma.
Browse Intraocular Lymphoma studies →Rayner Intraocular Lenses Limited is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients aged 22 years or older who are scheduled for bilateral cataract surgery as part of routine clinical care and are in accordance with the study's inclusion and exclusion criteria.
Eligible subjects must meet all the following inclusion criteria in both eyes.
Female subjects must be 1-year , surgically sterilized, or if must use a stabilized and acceptable form of from the beginning throughout the end of the study.
Stabilized and acceptable contraception methods include at least one of the following: intrauterine (intrauterine device) or hormonal (oral, injection, patch, implant, ring) for at least 3 months, barrier with spermicide (condom, diaphragm), or abstinence.
Eligible subjects must not meet any of the following exclusion criteria. Subjects may not participate if either eye meets any of the ocular exclusion criteria:
Irregular astigmatism in any eye
Additional Exclusion Criteria at the Time of Surgery:
Subjects who do not meet exclusion criteria described in section 6.2 and are enrolled in the study may present findings during surgery that preclude inclusion of performance data in the investigation and thus need to be excluded from data collection post operatively. The following general exclusion criteria shall be considered during surgery for either eye:
If the IOL has touched the eye, it should be noted if the reason for exclusion is related to the IOL itself and/or any (e.g. IOL or insertion device defect causing capsular damage, malfunction of insertion device).
If the IOL has touched the eye, the subject should be followed, for safety, until completion of the investigation.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients scheduled for routine bilateral cataract surgery as part of their standard clinical care. All participants receive the RayOne RAO800S non-toric monofocal intraocular lens with orientation marks.
Primary Effectiveness Endpoint - IOL rotation
Percentage of RayOne Model RAO800S IOLs with IOL rotation at Visit 4 (as determined by photographic method using baseline image at day of surgery) less than * 10 degrees in 90% of the cases as described in ISO 11979-7:2024. * 20 degrees in 95% of the cases as described in ISO 11979-7:2024.
Time frame: 120 to 150 days post-operatively (Visit 4)
Secondary Effectiveness Endpoints - Stability of IOL axis orientation
Stability of IOL axis orientation, expressed as percentage of IOLs that rotate ≤ 5 degrees postoperatively between 30 to 60 days (Visit 3) and 120 to 150 days (Visit 4) as described in the ANSI Z80.30-2018. This criterium is passed if 90% of the IOLs in the treated eyes rotate ≤ 5 degrees between the mentioned visits.
Time frame: 120 to 150 days post-operatively (Visit 4)
Secondary Effectiveness Endpoints - Axis misalignment
Axis misalignment, defined as the absolute difference between intended IOL axis orientation and Visit 4, (as determined by photographic method using baseline image at the day of surgery) shall be less than * 10 degrees in 90% of the cases as described in ANSI Z80.30-2018 * 20 degrees in 95% of the cases as described in ANSI Z80.30-2018.
Time frame: 120 to 150 days post-operatively (Visit 4)
Secondary Safety Endpoints - Rate of CDVA 0.30 logMAR
Rate of CDVA 0.30 logMAR or better at 120 to 150 days post-operatively (Visit 4) shall not exceed the ISO SPE threshold rates as described in ISO 11979-7:2024 (Table E.3)
Time frame: 120 to 150 days post-operatively (Visit 4)
No study locations are listed for this record.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rayner Intraocular Lenses Limited